用于治疗多重耐药人类免疫缺陷病毒的依巴利珠单抗治疗后乙肝再激活
Reactivation of Hepatitis B After Ibalizumab Therapy for Multidrug-Resistant Human Immunodeficiency Virus.
作者信息
Kaplan Alyson, DeHaan Elliott, Maltz Charles
机构信息
Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell School of Medicine, New York Presbyterian, New York, NY.
Division of Infectious Disease, Department of Medicine, Weill Cornell School of Medicine, New York Presbyterian, New York, NY.
出版信息
ACG Case Rep J. 2021 May 19;8(5):e00594. doi: 10.14309/crj.0000000000000594. eCollection 2021 May.
Despite the decreasing morbidity associated with the human immunodeficiency virus (HIV), a large percentage of persons with HIV have at least 1 drug resistance mutation. Ibalizumab, a recently approved drug, targets multidrug-resistant HIV. We present a case of reactivation of hepatitis B after initiation of ibalizumab therapy.
尽管与人类免疫缺陷病毒（HIV）相关的发病率在下降，但很大一部分HIV感染者至少有1种耐药突变。最近获批的药物依巴利珠单抗可靶向多重耐药的HIV。我们报告了1例依巴利珠单抗治疗开始后乙型肝炎再激活的病例。
Zotero 插件